Systemic lupus erythematosus: new diagnostic and therapeutic approaches

S Lazar, JM Kahlenberg - Annual review of medicine, 2023 - annualreviews.org
Systemic lupus erythematosus (SLE) is a devastating autoimmune disease that can result in
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …

Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal …

MF Ugarte-Gil, A Mak, J Leong… - Lupus science & …, 2021 - lupus.bmj.com
Objective In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC)
exposure are known to contribute to irreversible organ damage. We aimed to examine the …

Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 …

EF Morand, RA Furie, IN Bruce, EM Vital… - The Lancet …, 2022 - thelancet.com
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease
characterised by multisystem involvement. We aimed to evaluate the efficacy of anifrolumab …

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus

R Furie, EF Morand, AD Askanase, EM Vital… - Lupus, 2021 - journals.sagepub.com
Background Systemic lupus erythematosus (SLE) management objectives include
preventing disease flares while minimizing glucocorticoid exposure. Pooled data from the …

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

R Tummala, G Abreu, L Pineda, MA Michaels… - Lupus science & …, 2021 - lupus.bmj.com
Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …

Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort …

R Kandane-Rathnayake, V Golder… - The Lancet …, 2022 - thelancet.com
Background Treat-to-target goals for patients with systemic lupus erythematosus (SLE) have
been validated to protect against organ damage and to improve quality of life. We aimed to …

'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study

R Kandane-Rathnayake, W Louthrenoo, A Hoi… - Arthritis Research & …, 2022 - Springer
Background The unmet need in systemic lupus erythematosus (SLE) with the current
standard of care is widely recognised, but few studies have quantified this. The recent …

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus

EF Morand, G Abreu, RA Furie, V Golder… - Annals of the …, 2023 - ard.bmj.com
Objectives In patients with systemic lupus erythematosus (SLE), lupus low disease activity
state (LLDAS) attainment is associated with improved outcomes. We investigated LLDAS …

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials

Y Tanaka, R Tummala - Modern Rheumatology, 2021 - academic.oup.com
Chronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus
erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the …

Advances in the management of systemic lupus erythematosus

EF Morand, R Fernandez-Ruiz, A Blazer, TB Niewold - bmj, 2023 - bmj.com
Systemic lupus erythematosus (SLE) is a severe multisystem autoimmune disease that can
cause injury in almost every body system. While considered a classic example of …